Viewing data from:

LOARGYS

BLA

PEGZILARGINASE-NBLN | B761211 | IMMEDICA PHARMA AB

1 product0 Purple Book patents

Biologic LOEProtected

Estimated date when biosimilar competition may begin

February 23, 2038(4129 days remaining)

Regulatory Exclusivities

Type	Expiry	Status	Source
12-Year BPCIA	Feb. 23, 2038	Active	Computed

Purple Book Patents

No listed patents in Purple Book.

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Purple Book (Biologics)

BLA 761211 | 2 presentations

351(a) ReferenceLicensedCDERInjection

Proper Name

pegzilarginase-nbln

Applicant

Immedica Pharma AB

Approval Date

February 23, 2026

2MG/0.4ML — Single-Dose Vial (Intravenous, Subcutaneous)

5MG/ML — Single-Dose Vial (Intravenous, Subcutaneous)

Source: FDA Purple Book (purplebooksearch.fda.gov).

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Feb 24, 2026	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.1MG/KG

▴

Injectable; Injection | Approved: 2026-02-23 00:00:00

No patent or exclusivity listings for this strength.